Development of cell adhesion molecule antagonists as therapeutics for asthma and COPD

Pulmonary Pharmacology and Therapeutics

Volumn 17, Issue 1, 2004, Pages 1-10

  Vanderslice, Peter ^a   Biediger, Ronald J ^a   Woodside, Darren G ^a   Berens, Kurt L ^a   Holland, George W ^a   Dixon, Richard A F ^a  

^a TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

Asthma; Cell adhesion; Therapeutics

Indexed keywords

1031; 683699; ANTIASTHMATIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BIMOSIAMOSE; BIO 1211; CARBOHYDRATE DERIVATIVE; CD29 ANTIGEN ANTAGONIST; CELL ADHESION MOLECULE ANTAGONIST; CYLEXIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1 MONOCLONAL ANTIBODY; GW 559090; INTEGRIN; IVL 745; L SELECTIN MONOCLONAL ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1 ANTAGONIST; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD29; NATALIZUMAB; P SELECTIN GLYCOPROTEIN LIGAND 1; PROBUCOL SUCCINATE; R 411; RBX 7796; SELECTIN ANTAGONIST; TR 14035; UNCLASSIFIED DRUG;

AEROSOL; ALLERGIC ASTHMA; ASTHMA; CELL ACTIVATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG TARGETING; DRUG TOLERABILITY; ENTERITIS; HUMAN; IMMUNE DEFICIENCY; INFLAMMATORY DISEASE; LUNG INJURY; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REPRODUCTIVE TOXICITY; RESTENOSIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOSIS;

EID: 0344552292     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pupt.2003.10.004     Document Type: Review

References (115)

1. Trends in Asthma Morbidity and Mortality. American Lung Association, Epidemiology and Statistics Unit, Best Practices and Program Services; February 2002.
2. Trends in Chronic Bronchitis and Emphysema: Morbidity and Mortality. American Lung Association, Epidemiology and Statistics Unit, Best Practices and Program Services; March 2002.
3. Maddox L., Schwartz D.A. The pathophysiology of asthma. Annu Rev Med. 53:2002;477-498.
4. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med. 343:2000;269-280.
5. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76:1994;301-314.
6. Tedder T.F., Steeber D.A., Chen A., Engel P. The selectins: vascular adhesion molecules. FASEB J. 9:1995;866-873.
7. Vestweber D. The selectins: initiators of leukocyte endothelial adhesion. 1997;1-2 Harwood Academic Publishers, Netherlands.
8. Vestweber D. Ligand specificity of the selectins. J Cell Biochem. 61:1996;585-591.
9. Kansas G.S. Selectins and their ligands: current concepts and controversies. Blood. 88:1996;3259-3287.
10. Foxall C., Watson S.R., Dowbenko D., Fennie C., Lasky L.A., Kiso M., Hasegawa A., Asa D., Brandley B.K. The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide. J Cell Biol. 117:1992;895-902.
11. Berg E.L., Robinson M.K., Mansson O., Butcher E.C., Magnani J.L. A carbohydrate domain common to both sialyl Le(a) and sialyl Le(X) is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. J Biol Chem. 266:1991;14869-14872.
12. Wilkins P.P., Moore K.L., McEver R.P., Cummings R.D. Tyrosine sulfation of P-selectin glycoprotein ligand-1 is required for high affinity binding to P-selectin. J Biol Chem. 270:1995;22677-22680.
13. Goetz D.J., Greif D.M., Ding H., Camphausen R.T., Howes S., Comess K.M., Snapp K.R., Kansas G.S., Luscinskas F.W. Isolated P-selectin glycoprotein ligand-1 dynamic adhesion to P- and E-selectin. J Cell Biol. 137:1997;509-519.
14. Tu L., Chen A., Delahunty M.D., Moore K.L., Watson S.R., McEver R.P., Tedder T.F. L-selectin binds to P-selectin glycoprotein ligand-1 on leukocytes: interactions between the lectin, epidermal growth factor, and consensus repeat domains of the selectins determine ligand binding specificity. J Immunol. 157:1996;3995-4004.
15. Steegmaier M., Levinovitz A., Isenmann S., Borges E., Lenter M., Kocher H.P., Kleuser B., Vestweber D. The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor. Nature. 373:1995;615-620.
16. Baumheter S., Singer M.S., Henzel W., Hemmerich S., Renz M., Rosen S.D., Lasky L.A. Binding of L-selectin to the vascular sialomucin CD34. Science. 262:1993;436-438.
17. Lasky L.A., Singer M.S., Dowbenko D., Imai Y., Henzel W.J., Grimley C., Fennie C., Gillett N., Watson S.R., Rosen S.D. An endothelial ligand for L-selectin is a novel mucin-like molecule. Cell. 69:1992;927-938.
18. Berg E.L., McEvoy L.M., Berlin C., Bargatze R.F., Butcher E.C. L-selectin-mediated lymphocyte rolling on MAdCAM-1. Nature. 366:1993;695-698.
19. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell. 110:2002;673-687.
20. Hemler M.E., Huang C., Takada Y., Scharz L., Strominger J.L., Clabby M.L. Characterization of the cell surface heterodimer VLA-4 and related peptides. J Biol Chem. 262:1987;11478.
21. Bochner B.S., Luscinskas F.W., Gimbrone M.A., Newman W., Sterbinsky S.A., Derse-Anthony C.P., Klunk D., Schleimer R.P. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cell: contributions of endothelial cell adhesion molecules. J Exp Med. 173:1991;1553.
22. Kubes P., Niu X.F., Smith C.W., Kehrli M.E. Jr., Reinhardt P.H., Woodman R.C. A novel beta 1-dependent adhesion pathway on neutrophils: a mechanism invoked by dihydrocytochalasin B or endothelial transmigration. FASEB J. 9:1995;1103-1111.
23. Issekutz T.B., Miyasaka M., Issekutz A.C. Rat blood neutrophils express very late antigen 4 and it mediates migration to arthritic joint and dermal inflammation. J Exp Med. 183:1996;2175-2184.
24. Erle D.J., Briskin M.J., Butcher E.C., Garcia-Pardo A., Lazarovits A.I., Tidswell M. Expression and function of the MAdCAM-1 receptor, integrin α4β7, on human leukocytes. J Immunol. 153:1994;517.
25. Elices M.J., Osborn L., Takada Y., Crouse C., Luhowskyj S., Hemler M.E., Lobb R.R. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4/fibronectin binding site. Cell. 69:1990;577.
26. Ruegg C., Postigo A.A., Sikorski E.E., Butcher E.C., Pytela R., Erle D.J. Role of integrin α4β7/α4βP in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering. J Cell Biol. 117:1992;179.
27. Wayner E.A., Garcia-Pardo A., Humpheries M.J., McDonald J.A., Carter W.G. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol. 109:1989;1321.
28. Osborn L., Hession C., Tizard R., Vassallo C., Luhowskyj S., Chi-Rosso G., Lobb R. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell. 59:1989;1203-1211.
29. Berlin C., Berg E.L., Briskin M.J., Andrew D.P., Kilshaw P.J., Holzmann B., Weissman I.L., Hamann A., Butcher E.C. α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 74:1993;85.
30. Palmer E.L., Ruegg C., Ferrando R., Pytela R., Sheppard D. Sequence and tissue distribution of the integrin alpha 9 subunit, a novel partner of beta 1 that is widely distributed in epithelia and muscle. J Cell Biol. 123:1994;1289-1297.
31. Taooka Y., Chen J., Yednock T., Sheppard D. The integrin alpha9beta1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-1. J Cell Biol. 145:1999;413-420.
32. Mizgerd J.P., Kubo H., Kutkoski G.J., Bhagwan S.D., Scharffetter- Kochanek K., Beaudet A.L., Doerschuk C.M. Neutrophil emigration in the skin, lungs, and peritoneum: different requirements for CD11/CD18 revealed by CD18-deficient mice. J Exp Med. 186:1997;1357-1364.
33. Hawkins H.K., Heffelfinger S.C., Anderson D.C. Leukocyte adhesion deficiency: clinical and postmortem observations. Pediatr Pathol. 12:1992;119-130.
34. Grayson M.H., Van der Vieren M., Gallatin W.M., Hoffman P.A., Bochner B.S. Expression of a novel β2 integrin (αdβ2) on human leukocytes and mast cells. J Allergy Clin Immunol. 99:1997;5386.
35. Grayson M.H., Van der Vieren M., Sterbinsky S.A., Michael Gallatin W., Hoffman P.A., Staunton D.E., Bochner B.S. alphadbeta2 integrin is expressed on human eosinophils and functions as an alternative ligand for vascular cell adhesion molecule 1 (VCAM-1). J Exp Med. 188:1998;2187-2191.
36. Berlin C., Bargatze R.F., Campbell J.J., von Andrian U.H., Szabo M.C., Hasslen S.R., Nelson R.D., Berg E.L., Erlandsen S.L., Butcher E.C. α4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell. 80:1995;413.
37. Van der Vieren M., Crowe D.T., Hoekstra D., Vazeux R., Hoffman P.A., Grayson M.H., Bochner B.S., Gallatin W.M., Staunton D.E. The leukocyte integrin alpha D beta 2 binds VCAM-1: evidence for a binding interface between I domain and VCAM-1. J Immunol. 163:1999;1984-1990.
38. Henderson R.B., Lim L.H., Tessier P.A., Gavins F.N., Mathies M., Perretti M., Hogg N. The use of lymphocyte function-associated antigen (LFA)-1-deficient mice to determine the role of LFA-1, Mac-1, and alpha4 integrin in the inflammatory response of neutrophils. J Exp Med. 194:2001;219-226.
39. Salas A., Shimaoka M., Chen S., Carman C.V., Springer T. Transition from rolling to firm adhesion is regulated by the conformation of the I domain of the integrin lymphocyte function-associated antigen-1. J Biol Chem. 277:2002;50255-50262.
40. Constantin G., Majeed M., Giagulli C., Piccio L., Kim J.Y., Butcher E.C., Laudanna C. Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity. 13:2000;759-769.
41. Dustin M.L., Springer T.A. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol. 107:1988;321-331.
42. Staunton D.E., Dustin M.L., Springer T.A. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature. 339:1989;61-64.
43. Diamond M.S., Staunton D.E., de Fougerolles A.R., Stacker S.A., Garcia-Aguilar J., Hibbs M.L., Springer T.A. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol. 111:1990;3129-3139.
44. Xie J., Li R., Kotovuori P., Vermot-Desroches C., Wijdenes J., Arnaout M.A., Nortamo P., Gahmberg C.G. Intercellular adhesion molecule-2 (CD102) binds to the leukocyte integrin CD11b/CD18 through the A domain. J Immunol. 155:1995;3619-3628.
45. Miller L.J., Schwarting R., Springer T.A. Regulated expression of the Mac-1, LFA-1, p150,95 glycoprotein family during leukocyte differentiation. J Immunol. 137:1986;2891-2900.
46. Shang X.Z., Issekutz A.C. Contribution of CD11a/CD18, CD11b/CD18, ICAM-1 (CD54) and -2 (CD102) to human monocyte migration through endothelium and connective tissue fibroblast barriers. Eur J Immunol. 28:1998;1970-1979.
47. Issekutz A.C., Rowter D., Springer T.A. Role of ICAM-1 and ICAM-2 and alternate CD11/CD18 ligands in neutrophil transendothelial migration. J Leukoc Biol. 65:1999;117-126.
48. Albelda S.M., Oliver P.D., Romer L.H., Buck C.A. EndoCAM: a novel endothelial cell-cell adhesion molecule. J Cell Biol. 110:1990;1227-1237.
49. Sun Q.H., DeLisser H.M., Zukowski M.M., Paddock C., Albelda S.M., Newman P.J. Individually distinct Ig homology domains in PECAM-1 regulate homophilic binding and modulate receptor affinity. J Biol Chem. 271:1996;11090-11098.
50. Vaporciyan A.A., DeLisser H.M., Yan H.C., Mendiguren I.I., Thom S.R., Jones M.L., Ward P.A., Albelda S.M. Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science. 262:1993;1580-1582.
51. Chavakis T., Preissner K.T., Santoso S. Leukocyte trans-endothelial migration: JAMs add new pieces to the puzzle. Thromb Haemost. 89:2003;13-17.
52. Cunningham S.A., Rodriguez J.M., Arrate M.P., Tran T.M., Brock T.A. JAM2 interacts with alpha4beta1. Facilitation by JAM3. J Biol Chem. 277:2002;27589-27592.
53. Ostermann G., Weber K.S., Zernecke A., Schroder A., Weber C. JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol. 3:2002;151-158.
54. Santoso S., Sachs U.J., Kroll H., Linder M., Ruf A., Preissner K.T., Chavakis T. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med. 196:2002;679-691.
55. de Fougerolles A.R., Sprague A.G., Nickerson-Nutter C.L., Chi-Rosso G., Rennert P.D., Gardner H., Gotwals P.J., Lobb R.R., Koteliansky V.E. Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. J Clin Invest. 105:2000;721-729.
56. Fiorucci S., Mencarelli A., Palazzetti B., Sprague A.G., Distrutti E., Morelli A., Novobrantseva T.I., Cirino G., Koteliansky V.E., de Fougerolles A.R. Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity. 17:2002;769-780.
57. Krieglstein C.F., Cerwinka W.H., Sprague A.G., Laroux F.S., Grisham M.B., Koteliansky V.E., Senninger N., Granger D.N., de Fougerolles A.R. Collagen-binding integrin alpha1beta1 regulates intestinal inflammation in experimental colitis. J Clin Invest. 110:2002;1178-1182.
58. Rao W.H., Hales J.M., Camp R.D. Potent costimulation of effector T lymphocytes by human collagen type I. J Immunol. 165:2000;4935-4940.
59. Gotham S. IDDB Meeting Report. Antisense and SiRNA Technologies; February 12-13, 2003.
60. AtheroGenics Inc press release; January 14, 2003.
61. Liu G., Huth J.R., Olejniczak E.T., Mendoza R., DeVries P., Leitza S., Reilly E.B., Okasinski G.F., Fesik S.W., von Geldern T.W. Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/ intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. J Med Chem. 44:2001;1202-1210.
62. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 7:2001;687-692.
63. Gundel R.H., Wegner C.D., Torcellini C.A., Clarke C.C., Haynes N., Rothlein R., Smith C.W., Letts L.G. Endothelial leukocyte adhesion molecule-1 mediates antigen-induced acute airway inflammation and late-phase airway obstruction in monkeys. J Clin Invest. 88:1991;1407-14111.
64. DeSanctis G.T., Wolyniec W.W., Green F.H., Qin S., Jiao A., Finn P.W., Noonan A.A., Joetham A.A., Gelfand E., Doerschuk C.M., Drazen J.M. Reduction of allergic airway responses in P-selectin-deficient mice. J Appl Physiol. 83:1997;681-687.
65. Abraham W.M., Ahmed A., Sabater J.R., Lauredo I.T., Botvinnokova Y., Bjercke R.J., Hu X., Revelle M.B., Kogan T.P., Scott I.L., Dixon R.A.F., Yeh E.T.H., Beck P.J. Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsivess in allergic sheep. Am J Respir Crit Care Med. 159:1999;1205-1214.
66. Becker D.J., Lowe J.B. Leukocyte adhesion deficiency type II. Biochim Biophys Acta. 1455:1999;193-204.
67. Bullard D.C., Kunkel E.J., Kubo H., Hicks M.J., Lorenzo I., Doyle N.A., Doerschuk C.M., Ley K., Beaudet A.L. Infectious susceptibility and severe deficiency of leukocyte rolling and recruitment in E-selectin and P-selectin double mutant mice. J Exp Med. 183:1996;2329-2336.
68. Jung U., Ley K. Mice lacking two or all three selectins demonstrate overlapping and distinct functions for each selectin. J Immunol. 162:1999;6755-6762.
69. Lefer D.J., Flynn D.M., Phillips M.L., Ratcliffe M., Buda A.J. Novel sialyl Lewisx analog attenuates neutrophil accumulation and myocardial necrosis after ischemia and reperfusion. Circulation. 90:1994;2390-2401.
70. Dulkanchainun T.S., Goss J.A., Imagawa D.K., Shaw G.D., Anselmo D.M., Kaldas F., Wang T., Zhao D., Busuttil A.A., Kato H., Murray N.G., Kupiec-Weglinski J.W., Busuttil R.W. Reduction of hepatic ischemia/reperfusion injury by a soluble P-selectin glycoprotein ligand-1. Ann Surg. 227:1998;832-840.
71. Hayward R., Campbell B., Shin Y.K., Scalia R., Lefer A.M. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemia reperfusion injury in cats. Cardiovasc Res. 41:1999;65-76.
72. Silver M.J., Sutton J.M., Hook S., Lee P., Malycky J.L., Phillips M.L., Ellis S.G., Topol E.J., Nicolini F.A. Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 92:1995;492-499.
73. Kumar A., Villani M.P., Patel U.K., Keith J.C. Jr., Schaub R.G. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation. 99:1999;1363-1369.
74. Barron M.K., Lake R.S., Buda A.J., Tenaglia A.N. Intimal hyperplasia after balloon injury is attenuated by blocking selectins. Circulation. 96:1997;3587-3592.
75. Kusaka M., Zandi-Nejad K., Kato S., Beato F., Nagano H., Shaw G.D., Tilney N.L. Exploitation of the continuum between early ischemia/reperfusion injury and host alloresponsiveness: indefinite kidney allograft survival by treatment with a soluble P-selectin ligand and low-dose cyclosporine in combination. Transplantation. 67:1999;1255-1261.
76. Cytel Corporation press release; March 30, 1999.
77. Neose Technologies Inc press release; May 10, 2002.
78. Protein Design Labs Inc press release; November 16, 1999.
79. Kogan T.P., Dupré B., Bui H., McAbee K.L., Kassir J.M., Scott I.L., Hu X., Vanderslice P., Beck P.J., Dixon R.A.F. Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3- carboxymethylphenyl)-4-(2-α-D-mannopyranosyloxy)-phenyl]hexane (TBC1269). J Med Chem. 41:1998;1099-1111.
80. Palma Vargas J.M., Toledo-Pereyra L., Dean R.E., Harkema J.M., Dixon R.A.F., Kogan T.P. Small molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion. J Am Coll Surg. 185:1997;365-372.
81. Ramos-Kelly J.R., Toledo-Pereyra L.H., Jordan J.A., Rivera-Chavez F.A., Dixon R.A.F., Ward P.A. Upregulation of lung chemokines associated with hemorrhage is reversed with a small molecule multiple selectin inhibitor. J Am Coll Surg. 189:1999;546-553.
82. Encysive Pharmaceuticals press release; September 9, 1998.
83. Revotar Biopharmaceuticals AG press release; February 25, 2002.
84. Revotar Biopharmaceuticals AG press release; August 5, 2003.
85. Pesci A., Balbi B., Majori M., Cacciani G., Bertacco S., Alciato P., Donner C.F. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J. 12:1998;380-386.
86. Keatings V.M., Collins P.D., Scott D.M., Barnes P.J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 153:1996;530-534.
87. Mulligan M.S., Watson S.R., Fennie C., Ward P.A. Protective effects of selectin chimeras in neutrophil-mediated lung injury. J Immunol. 151:1993;6410-6417.
88. Mulligan M.S., Lowe J.B., Larsen R.D., Paulson J., Zheng Z.L., DeFrees S., Maemura K., Fukuda M., Ward P.A. Protective effects of sialylated oligosaccharides in immune complex-induced acute lung injury. J Exp Med. 178:1993;623-631.
89. Henderson W.R. Jr., Chi E.Y., Albert R.K., Chu S.J., Lamm W.J., Rochon Y., Jonas M., Christie P.E., Harlan J.M. Blockade of CD49d (alpha4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J Clin Invest. 100:1997;3083-3092.
90. Hojo M., Maghni K., Issekutz T.B., Martin J.G. Involvement of alpha-4 integrins in allergic airway responses and mast cell degranulation in vivo. Am J Respir Crit Care Med. 158:1998;1127-1133.
91. Pretolani M., Ruffie C., Lapa e Silva J.R., Joseph D., Lobb R.R., Vargaftig B.B. Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways. J Exp Med. 180:1994;795-805.
92. Metzger W.J. Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors. Springer Semin Immunopathol. 16:1995;467-478.
93. Abraham W.M., Seilczak M.W., Ahmed A., Cortes A., Lauredo I.T., Kim J., Pepinsky B., Benjamin C.D., Leone D.R., Lobb R.R., Weller P.F. α4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J Clin Invest. 93:1994;776.
94. Abraham W.M., Gill A., Ahmed A., Sielczak M.W., Lauredo I.T., Botinnikova Y., Lin K.C., Pepinsky B., Leone D.R., Lobb R.R., Adams S.P. A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med. 162:2000;603-611.
95. Shimizu Y., van Seventer G.A., Horgan K.J., Shaw S. Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J Immunol. 145:1990;59-67.
96. Burkly L.C., Jakubowski A., Newman B.M., Rosa M.D., Chi-Rosso G., Lobb R.R. Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation. Eur J Immunol. 21:1991;2871-2875.
97. Bednarczyk J.L., McIntyre B.W. A monoclonal antibody to VLA-4 alpha-chain (CDw49d) induces homotypic lymphocyte aggregation. J Immunol. 144:1990;777-784.
98. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W. International natalizumab multiple sclerosis trial group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 348:2003;15-23.
99. Ghosh S., Goldin E., Gordon F.H., Malchow H.A., Rask-Madsen J., Rutgeerts P., Vyhnalek P., Zadorova Z., Palmer T., Donoghue S. Natalizumab pan-European study group. Natalizumab for active Crohn's disease. N Engl J Med. 348:2003;24-32.
100. Yang J.T., Rayburn H., Hynes R.O. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development. 121:1995;549-560.
101. Kwee L., Baldwin H.S., Shen H.M., Stewart C.L., Buck C., Buck C.A., Labow M.A. Defective development of the embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. Development. 121:1995;489-503.
102. Gurtner G.C., Davis V., Li H., McCoy M.J., Sharpe A., Cybulsky M.I. Targeted disruption of the murine VCAM1 gene: essential role of VCAM-1 in chorioallantoic fusion and placentation. Genes Dev. 9:1995;1-14.
103. Spence S., Vetter C., Hagmann W.K., Van Riper G., Williams H., Mumford R.A., Lanza T.J., Lin L.S., Schmidt J.A. Effects of VLA-4 antagonists in rat whole embryo culture. Teratology. 65:2002;26-37.
104. Merck & Co. Company Communication; March 29, 2000.
105. Biogen, Company Communication; March 30, 2000.
106. Aventis Pharma AG, Company Communication; February 13, 2002.
107. Aventis Pharma AG, Company Communication; May 8, 2002.
108. Aventis Pharma AG, Company Communication; May 15, 2001.
109. Aventis Pharma AG, Company Communication; June 18, 2002.
110. Roche Holding AG, Company Presentation; April 16, 2002.
111. GlaxoSmithKline plc, Company Publication; February 12, 2003.
112. GlaxoSmithKline plc, Company Publication; October 23, 2002.
113. Celltech Group plc, Press Release; March 18, 2003.
114. Ranbaxy Laboratories Ltd, World Wide Website; September 24, 2002.
115. Texas Biotechnology Corporation, Press Release; February 26, 2002.